文献速递胸部肿瘤放疗

倾向性评分匹配分析:IIIA-N2期非小细胞肺癌术后放疗的生存获益

Propensity score-matching analysis of postoperative radiotherapy for stage IIIA-N2 non-small cell lung cancer using the Surveillance, Epidemiology, and End Results database.
PubMed 文献 · Radiat Oncol · 2017-06-13

基于SEER数据库2004至2013年3334例已切除IIIA-N2期NSCLC患者,经倾向性评分匹配后比较术后放疗(PORT)与未放疗各744例。PORT提高总生存(HR 0.793,p=0.001)和肺癌特异性生存(HR 0.837,p=0.022),OS获益主要见于<60岁和行肺叶切除术者。

要点

  • 匹配后PORT提高OS(HR 0.793,p=0.001)和LCSS(HR 0.837,p=0.022)。
  • <60岁患者PORT的5年OS为35.4%对28.9%(p=0.026)。
  • 肺叶切除者PORT的5年OS为43.5%对34.5%(p=0.001),5年LCSS为48.3%对42.3%(p=0.036)。

核心结论

  • 已切除IIIA-N2期NSCLC的PORT生存获益主要体现在<60岁或行肺叶切除术的患者。

研究设计与样本

  • 回顾性队列研究,基于SEER数据库2004至2013年3334例已切除IIIA-N2期NSCLC患者。
  • 采用倾向性评分匹配平衡基线特征,匹配后PORT组与无PORT组各744例。

主要发现

  • 匹配后PORT较无PORT提高OS(HR 0.793;p=0.001)和LCSS(HR 0.837;p=0.022)。
  • OS获益主要见于<60岁患者(5年OS 35.4%对28.9%;p=0.026)和肺叶切除术患者(5年OS 43.5%对34.5%;p=0.001)。
  • LCSS获益在肺叶切除术患者中显著(5年LCSS 48.3%对42.3%;p=0.036)。

关键数值与推荐

  • PORT组与无PORT组匹配后各744例,比较OS和LCSS。
  • OS的HR为0.793(p=0.001),LCSS的HR为0.837(p=0.022)。

临床怎么用

  • 对<60岁或行肺叶切除术的已切除IIIA-N2期NSCLC患者,可考虑PORT以改善生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To investigate the effects of postoperative radiotherapy (PORT) on the survival of patients with resected stage IIIA-N2 non-small cell lung cancer (NSCLC). METHODS: A total of 3,334 patients with resected stage IIIA-N2 NSCLC in 2004 to 2013 were identified in the Surveillance, Epidemiology, and End Results database and stratified according to use of PORT. Propensity score-matching (PSM) methods were used to balance the baseline characteristics of patients who did (n = 744) or did not (n = 744) undergo PORT. Overall survival (OS) and lung cancer-specific survival (LCSS) were compared between these two patient groups. RESULTS: After PSM, PORT increased OS (hazard ratio, 0.793; p = 0.001) and LCSS (hazard ratio, 0.837; p = 0.022) compared with no PORT. The OS benefit for PORT was mainly seen in patients aged <60 years (5-year OS, 35.4% versus 28.9% for PORT versus no PORT, respectively; p = 0.026) and in those who underwent lobectomy (5-year OS, 43.5% versus 34.5% for PORT versus no PORT, respectively; p = 0.001). The LCSS benefit for PORT was significant in patients undergoing lobectomy (5-year LCSS, 48.3% versus 42.3% for PORT versus no PORT, respectively; p = 0.036). CONCLUSIONS: The survival benefits of PORT were primarily observed in patients with resected stage IIIA-N2 NSCLC who were <60 years of age or had undergone lobectomy.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Wei S, Xie M, Tian J, et al. Propensity score-matching analysis of postoperative radiotherapy for stage IIIA-N2 non-small cell lung cancer using the Surveillance, Epidemiology, and End Results database. Radiat Oncol. 2017. PMID: 28610591. doi:10.1186/s13014-017-0836-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。